Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Antidiabetic Properties of Rose Hip

This study has been completed.
Sponsor:
Information provided by:
Lund University
ClinicalTrials.gov Identifier:
NCT01316016
First received: March 15, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
  Purpose
The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Condition Intervention
Obesity
 Dietary Supplement: Rose hip

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons

Further study details as provided by Lund University:
Enrollment: 31
Study Start Date: April 2009
Study Completion Date: January 2011
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rose hip Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.

  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI > 30
  • willingness to participate in the study
  • willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

  • diabetes
  • previous or ongoing insulin treatment
  • abnormal thyroid status
  • abnormal liver status
  • abnormal kidney status
  • known gastrointestinal disorder
  • pregnancy
  • suspected allergy to ingredients of the drinks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01316016

Locations
Sweden
Endocrinology Clinic, Lund University Hospital
Lund, Sweden, SE-22185
Sponsors and Collaborators
Lund University
Investigators
Study Chair: Per Katzman, MD/PhD Lund University
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Cecilia Holm, Lund University
ClinicalTrials.gov Identifier: NCT01316016     History of Changes
Other Study ID Numbers: LUAFC002 
Study First Received: March 15, 2011
Last Updated: March 15, 2011
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Lund University:
obesity
glucose intolerance
cholesterol
blood pressure

ClinicalTrials.gov processed this record on September 29, 2016